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ABSTRACT
The Effect of Photobiomodulation Therapy on
Exercise-Induced Muscle Damage
Kathleen Nichole Thiriot
Department of Exercise Sciences, BYU
Master of Science
Purpose: To explore the difference between continuous and pulsed photobiomodulation
(PBMT) versus a placebo treatment when using a red-blue light combination over multiple
treatment sessions to decrease the symptoms of muscle damage in the quadriceps muscle after a
bout of muscle damaging exercise.
Methods: Thirty-six healthy, nonactive male and female participants were randomly
assigned to one of three groups: continuous PBMT, pulsed PBMT, and placebo treatment.
Participants were assessed for muscle damage with knee extension maximal isometric and
isokinetic contractions, as well as Visual Analog Scale (VAS) and Lower Extremity Functional
Scale (LEFS) scores. Blood creatine kinase (CK) was also analyzed. Participants were given
treatment immediately prior to undergoing a bout of damaging eccentric exercise. Participants
were treated with PBMT for the next 4 consecutive days for a total of 5 treatments.
Results: The continuous treatment group lost significantly less isokinetic average peak
torque than the placebo treatment when averaged across all time points postexercise. However,
for isometric testing, the continuous group had more reduction in force compared to the placebo
group. Between the treatment groups, the continuous treatment group had significantly more
muscle soreness measured by the VAS and had significantly less function in daily tasks reported
on the LEFS patient-oriented outcome scale. There was no significant difference in level of
creatine kinase between the treatment groups.
Conclusion: Pulsed photobiomodulation treatments had no significant effect when
compared to the placebo group. Continuous photobiomodulation helped to reduce isokinetic
force loss, yet exacerbated all other muscle damage markers following exercise relative to the
placebo condition.

Keywords: photobiomodulation, phototherapy, LLLT, cold laser therapy, pulsed, continuous and
a combination of these
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INTRODUCTION
Individuals commonly experience exercise-induced muscle damage (EIMD) following an
unaccustomed physical activity.1 Muscle damage has been described as morphological changes
within the muscle including disruption of the sarcomeric Z-disc, in which structural damage
causes leakage of proteins into the blood.2 Evidence of EIMD includes disruption of intracellular
muscular structure, prolonged impairment of muscular function, stiffness and swelling,3 delayed
onset muscle soreness (DOMS), weakness and increases in circulating muscle proteins such as
creatine kinase (CK).4 Exercise-induced muscle damage most commonly occurs following an
eccentrically loaded exercise,3,5 potentially leading to pain and decreased muscle performance.
Many strategies have been used to decrease signs and symptoms associated with EIMD,
including ice massage, manual massage, ultrasound, and anti-inflammatory drugs.6-9
Recently there has been an increase in research focusing on the application of
photobiomodulation (PBMT) to reduce muscle damage and to increase recovery rate after
exercise.10 Photobiomodulation has been found to be effective in decreasing markers of muscle
damage when used prior to a muscle damaging bout of exercise.11,12 Several studies11-13 have
found that when subjects were irradiated before exercise, they had decreased circulating CK
activity,10 reduced impairment to maximum voluntary contraction12 and a decrease in perceived
pain and soreness in the days after exercise.11
Different PBMT parameters have been studied and suggested to have different responses
in the body. Most commonly, red and near infrared wavelengths of 600-1100 nm are used in
studies to decrease muscle damage. Some studies have used multi-wavelength-emitting devices
to produce a red wavelength, 640 nm, and two infrared wavelengths, 875 nm and 905nm,
simultaneously.11 Multi-wavelength-emitting PBMT devices have been found to be superior to
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placebo groups in reducing markers of muscle damage.11,14 Other studies have also found a
decrease in muscle damage from using only red wavelengths13,15 or only infrared
wavelengths.12,16,17 Blue light has been previously used to kill bacteria and decrease acne.18
However, until now, no studies have been performed to determine the effectiveness of blue light
on muscle damage following exercise.
Pulse duration is another parameter of PBMT that may be altered to achieve the desired
outcomes. Treatments can be continuous, when the stimulation is constant throughout the whole
treatment, or pulsed, when the stimulation goes on and off during the treatment. Pulsed PBMT
treatments, in combination with continuous treatments, have been shown to reduce markers of
muscle damage.13,19 Few studies have used only pulsed treatment parameters. De Marchi et al20
performed a study in which they compared continuous treatments to pulsed treatments for
decreasing muscle damage. It was found that the pulsed treatment groups had significantly less
CK activity and lower modified VAS scores for DOMS when compared to the continuous
treatment. Similar to other studies performed, De Marchi only had one treatment prior to the
muscle damaging bout of exercise. With this in mind, our goal was to explore the difference
between pulsed and continuous PBMT versus a placebo treatment when using a red-blue light
combination over multiple treatment sessions to decrease muscle damage markers after a bout of
exercise.
METHODS
Research Design
We used a placebo-controlled, randomized laboratory study in which participants were
divided into one of three treatment groups. These groups consisted of a continuous PBMT group,
pulsed PBMT group and a placebo group. Each participant came in for baseline measurements,
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then 2 to 3 days later participants were given a PBMT treatment and completed a muscledamaging protocol immediately following. After, participants went through strength testing and
muscle soreness tests. Each day following, participants came in for PBMT treatment, strength
and soreness testing. The schedule was as follows for the different measurements: Isometric
strength, isokinetic strength and muscle soreness were all tested at baseline, immediately
postexercise and 24 hours, 48 hours, 72 hours and 96 hours postexercise. Serum CK levels were
measured at baseline and again at 48 hours and 96 hours postexercise. Our dependent variables
for this study were isometric strength, isokinetic strength, muscle soreness, and serum CK. Our
independent variables were treatment group and time.
Procedures
All data collection occurred in the Human Performance Research Laboratory in the
Department of Exercise Sciences at a large western university. Each participant made 6 visits to
the Human Performance Research Laboratory. Baseline measurements were taken at the first
visit after eligibility was confirmed. During this visit, the participant’s age, weight, height, sex
and leg dominance information were recorded. The participant completed a visual analogue scale
(VAS) and lower extremity functional scale (LEFS) to determine level of soreness before
exercise. We then took a blood sample from an antecubital vein at the elbow to evaluate baseline
levels of serum CK. Baseline strength measurements were measured by isometric and isokinetic
dynamometry. Peak torque and average peak torque were recorded for the isometric test. Peak
torque, average peak torque and average power were recorded for the isokinetic test.
The second visit occurred 2 to 3 days following baseline measurements. During this
visit, the first dose of PBMT treatment was given for 30 minutes directly followed by the
eccentric exercise protocol. After this, participants went through isometric and isokinetic
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strength testing and recorded VAS and LEFS for soreness and function. Over the next 4
consecutive days, PBMT treatments were given, VAS and LEFS measurements were taken and
isometric and isokinetic strength tests were performed. Blood samples were taken again 48 hours
and 96 hours postexercise to determine levels of CK in the blood.
Participants
Participants for this study included 36 healthy males and females (males = 20, females =
16; age = 21–35, avg = 23; average height = 174.3 cm; average mass = 78.2 kg), with no
musculoskeletal injury to the lower limb within 3 months prior to the study. Participants were
classified as moderately active to not active meaning they participated in 30 minutes of physical
exercise 1 to 3 times per week or less for the past 6 months. Participants were excluded if they
were pregnant, had cardiovascular disease or cancer, suffered from epilepsy, or were classified as
more than moderately active. Participants were recruited from the local university community
and self-reported verbal responses to the study eligibility requirements. This study was reviewed
and approved by the Institutional Review Board for the Use of Human Subjects at our University
prior to the recruitment of subjects and collection of any data.
Photobiomodulation
Participants were randomly assigned into 1 of 3 treatment groups: continuous dosage,
pulsed dosage or a placebo group. All three groups were given treatment for 30 minutes before a
muscle-damaging bout of exercise, and before muscle testing in the next 4 consecutive days. The
researcher used the MJHIU treatment patches to deliver the PBMT treatment. Patches were 50 cm2
and the device produced a wavelength of 640 nm +/− 20 nm and 450 nm +/− 20 nm
simultaneously. The patches were attached to the body surface of the quadriceps muscles with a
hydrogel that also aided in transfer of the light. The PBMT device has a maximum pulsating
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laser power of 5.4 mW with an average combined power of 1.8 mW over the entire surface of the
patch. All PBMT treatments were administered in direct contact with the skin at 4 irradiation
sites shown in Figure 1. During a continuous power PBMT treatment, the power was produced
during the entire treatment. Pulsed treatments had intermittent periods alternating between the
device producing power and the device not producing power. The pulsed treatment had a 33%
duty cycle. The placebo treatment was given with the same device as the others, however it was
set in a mode in which no power was produced when the device was turned on. Treatments
occurred immediately prior to the muscle damaging protocol and before strength and soreness
testing over the next 4 consecutive days for a total of 5 treatments.
Muscle Damage Protocol
Participants participated in an eccentric exercise protocol as described by Deyhle et al.21
Participants were seated in the dynamometer chair adjusted in tilt, height, depth and recline.
Rotation of the shaft arm was adjusted so the fulcrum of the machine was lined up with the
participant’s knee for maximum comfort and movement ability. Participants began the protocol
by extending their knee and pushing against the lever arm with maximum force until they
reached 40 degrees of extension at a fixed rate of 180 degrees per second. Once participants
reached 40 degrees of extension, they continued to extend their knee and push against the lever
arm as it pushed them back into flexion at a rate of 120 degrees per second. Verbal
encouragement was given throughout the exercise as participants performed 10 sets of 10 reps
with a 1-minute rest between each set. Participants rested for 5 minutes and this protocol was
repeated 2 more times for a total of 30 sets or 300 reps.
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Evaluation of Strength Loss
Evaluation exercises to determine maximal isometric and isokinetic force production at
baseline and each day throughout the 5 days of treatment were performed on the dynamometer.
Participants were seated in the dynamometer chair and tilt, height, depth, recline and rotation of
the shaft arm were adjusted to fit the participant’s specific height and limb length. The
dynamometer straps were used to stabilize the participant to ensure use of only the quadriceps
muscles to accomplish the exercise. Straps were placed over both shoulders crossing the body at
the chest. Two more straps were placed around the waist and around the thigh of the involved
leg. Participants were allowed to perform 3 to 5 practice knee flexion/extension repetitions to
familiarize themselves with the test before testing occurred.
The isometric test was performed by contracting maximally against the stationary lever
arm at 70 degrees of flexion for 5 seconds, repeated 3 times with a 5-second rest between each
maximal effort. Verbal encouragement was given while they performed this action. Peak torque
and average peak torque were recorded and participants were allowed to rest for 2–3 minutes
before performing the isokinetic strength test. The isokinetic test was performed by the
participants giving maximum effort while performing 3 concentric knee flexion and extension
contractions against a lever arm moving at a fixed rate of 60º/sec. Verbal encouragement was
also given during this test. Peak torque, average peak torque and average power were recorded.
Evaluation of DOMS
Participants completed a modified 100 mm visual analogue scale (VAS) to measure their
perception of muscle soreness. A visual of a modified VAS pain scale is shown in Figure 2. The
modified VAS is a 100 mm horizontal line with anchor points at each end. The left anchor point
reads “not sore” and the right anchor point reads “extremely sore.” In the middle of the
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horizontal line reads “mildly sore.” Participants rated their pain by drawing a single vertical line
at the point that most closely described their pain. Researchers then measured their pain in mm.
Participants were asked to do a body weight squat before rating their overall pain at the time they
were filling out the form. Participants’ modified VAS scale was recorded at baseline, directly
before the treatment to see immediate effects of the treatment, after the muscle damaging
protocol, and each consecutive day of treatment directly following the PBMT treatment. At these
same time points, participants also completed the Lower Extremity Functional Scale (LEFS) via
Qualtrics which has a broader base of functional questions.
Blood Samples and Creatine Kinase Analysis
Blood samples for CK analysis were collected at baseline, 48 hours postexercise and 96
hours postexercise. Standardized phlebotomy procedures were followed and blood was taken
from the antecubital region of the participant’s arm to obtain 5 to 6 ml of blood. Blood was
immediately centrifuged, and serum was stored at −80ºC for later use. Creatine kinase levels
were then analyzed at Utah Valley Hospital, per their laboratory procedures.
Statistical Analysis
Data was analyzed with a repeated measures ANCOVA for each dependent variable.
Baseline values were tested as a covariate to account for potential individual variations. All
statistics were analyzed in JMP Pro (version 12, SAS Inc., Cary, NC) and the alpha level was set
at P ≤ 0.05. Data was normalized for analysis so isokinetic and isometric data was reported as
percent change in participant’s baseline values. VAS and LEFS were also normalized for
individual participants as the change in their score from their baseline score. A log
transformation was used to normalize CK analysis data.
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RESULTS
Isokinetic Force Production
There was no difference at baseline for isokinetic peak torque (F2,32 = 0.517, P = 0.602),
average peak torque (F2,32 = 0.924, P = 0.408), and average power between the 3 treatment
groups. Across all treatment groups, the eccentric muscle damaging protocol significantly
decreased peak torque (F5, = 5.16, P = 0.0002), average peak torque (F5, = 3.18, P = 0.009), and
average power (F5, = 3.019, P = 0.012) after exercise. Isokinetic peak torque (F5, = 2.629, P =
0.075), and average power (F2, = 1.861, P = 0.159) were not significantly different between the
treatment groups (treatment main effect) (Figure 3). On average, the continuous treatment group
significantly lost 18.25% less force for average peak torque and had a higher rate of recovery
when compared to the placebo treatment group (F5, = 3.709, P = 0.026) averaging across all time
points. There was no significant treatment x time interaction for any of the 3 isokinetic
measurements. Means and standard error isokinetic peak torque, average peak torque, and
average power are displayed in Figure 4.
Isometric
There was also no difference at baseline between the 3 treatment groups for isometric
peak torque (F = 1.035, P = .367) and average peak torque (F = .956, P = .395). Across all
treatment groups, the eccentric muscle damaging protocol significantly decreased peak torque (F
= 3.147, P = 0.001) and average peak torque (F = 3.98, P = 0.002) after exercise. The continuous
group lost 9.6% more force for peak torque when compared to the placebo group (P = 0.0428)
(Figure 5). There was no difference between the treatment groups across all time points for
average isometric torque (F = 2.609, P = 0.076). There was not a significant treatment x time
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interaction for either of the 2 isometric measurements. Means and standard error for isometric
peak torque and average peak torque are displayed in Figure 6.
Muscle Soreness
Baseline measurements were not significantly different between groups for VAS (F =
3.048, P = 0.061) and LEFS (F = 0.623, P = 0.543). Muscle soreness measured by VAS (F =
24.145, P = < .0001) increased due to the eccentric exercise across all time points and
functionality measured by LEFS (F = 18.34, P = < .0001) decreased across all time points (time
main effect). Between the treatment groups, the continuous treatment group had significantly
more muscle soreness measured by the VAS (F = 15.072, P = < .0001) and had significantly less
function reported on the LEFS patient oriented outcome scale (F = 14.042, P = < .0001) (Figure
7). There was not a significant treatment group x time interaction for either the LEFS or VAS
scales. Means and standard errors for the LEFS and VAS scales are displayed in Figure 8.
Creatine Kinase
There was no CK difference between the treatment groups at baseline (F = 1.444, P =
0.25). The eccentric exercise protocol significantly increased the concentration of CK (F =
12.057, P = < .0001) in the bloodstream across all time points (time main effect). However, there
was no significant difference between the treatment groups (F = 2.837, P = 0.064) (treatment
main effect). Means and standard errors for CK concentration are displayed in Figure 9.
DISCUSSION
This study was conducted to determine the effect of pulsed and continuous PBMT versus
a placebo treatment, when used prior to an eccentric exercise protocol and over multiple
treatment sessions, on muscle damage markers. For this particular study, we decided to perform
the irradiation treatment prior to the muscle damaging exercise based on previous research
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reporting superior results to studies in which treatment is given after exercise.11,12,19,22 The
eccentric muscle-damaging protocol immediately altered isometric and isokinetic muscle
performance, increased circulating CK activity and increased muscle soreness for all treatment
groups. Our results indicated no difference of CK activity throughout the treatment period
between the continuous, pulsed or placebo PBMT. We also found no difference between a pulsed
treatment and a placebo treatment in their affect toward the participants’ pain or in self-reported
lower extremity functionality. However, we found that those given a continuous PBMT
treatment reported greater pain levels, as reported by a modified VAS, and reduced self-reported
functionality, as reported by the LEFS test.
Previous research has found that continuous red/infrared and infrared PBMT treatments
prior to muscle-damaging exercise increases the ability of subjects to produce maximum
voluntary contraction (MVC).11,12 Regarding isokinetic contractions for our research, the
continuous treatment group lost significantly less average peak torque than the placebo treatment
group when averaged across all time points. In contrast, regarding isometric contractions, the
continuous group produced significantly less force than the placebo group. No previous studies
have used isometric contractions as a form of assessing muscle damage after exercise, and
although strength can differ based on age, height and sex,23 there were no significant differences
between the groups at baseline for either isokinetic or isometric strength tests. There is
conflicting research from previous studies about the relationship between isokinetic and
isometric exercise. Osternig et al27 found no evidence linking isokinetic strength values with
isometric strength values. However, Otis24 found a strong relationship between isokinetic and
isometric strength. Otis found position of the joint and velocity of the isokinetic measurement to
have a significant effect on strength. For our study, because we used only one joint angle and one
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velocity for isokinetic measurement, we may not have a broad enough understanding of what
was really happening. Therefore, further research should be performed to understand the
physiologic changes across different contractions after a PBMT treatment.
Antonialli et al11 found infrared PBMT treatments beneficial in decreasing DOMS
measured through VAS scores and increasing LEFS scores using a single continuous treatment
prior to exercise. However, we found that those given a continuous treatment to have
significantly more pain and decreased LEFS scores. We also found no difference between pulsed
and placebo groups for these subjective measures. Although our studies were very similar,
Antonialli et al11 only performed one PBMT treatment, whereas we gave multiple treatments
over an extended period of time. The multiple treatments would increase the total energy
delivered to the quadriceps muscle to 3456 J (4 treatments x 864 J per treatment) compared to
60, 180, or 300 J based on the randomly assigned group in the study performed by Antonialli et
al.11 Our data may be explained with the Arndt-Schulz principle which states that a weak
stimulus will accelerate activity and a stronger stimulus will increase activity further. However,
there comes a point when the stimuli reaches a peak and any stimuli over that threshold will
cause a negative response.25 Giving one continuous treatment prior to exercise may have been
enough to create a response, multiple treatments given over the healing period of time may have
caused an inhibitory effect on the tissue.
Conversely, our lack of results for our pulsed treatment group may be explained by a
shorter wavelength from our blue light as well as a lower power given. Our device had an
average power of 2.4 mW/cm2 whereas Antonialli et al11 used a devise that produced an average
power of 32.5 mW/cm2. Our PBMT treatment may have had a hard time penetrating the
treatment surface or not going very deep into the muscle and therefore giving us no results.
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Hashimi et al26 conducted a review of 33 studies determining the best parameters for
phototherapy. Nine of these studies directly compared a continuous phototherapy treatment to a
pulsed phototherapy treatment for conditions such as wound healing, pain, and nerve
regeneration. Although 7 of the 9 studies found the pulsed wavelength to be superior to
continuous and placebo treatments, our study found pulsed PBMT treatments to be very similar
to placebo treatments in decreasing the amount of muscle damage markers in the body after
muscle damaging exercise. We did not have a true control of participants who underwent the
muscle damaging exercise but did not receive any treatment. Therefore, we don’t know the full
extent of how the placebo effect may have affected the participants. We took our exercise
protocol from a study performed by Deyhle et al21 in which they performed no treatment for
participants after undergoing the exercise protocol. Participants from Deyhle et al had an
increase of muscle damage markers and returned to pre-exercise levels in a similar time frame as
participants in the placebo group in our study. We observed in our study that the body reacted
similarly to a sham treatment as it did with a pulsed treatment. Because our placebo group had
similar results to a group given no treatment, it is unlikely that our findings were affected by a
placebo effect.
We had several limitations for this study. Participants in this study were blinded, but the
researcher was not. Of the participants, most were university students in similar geographic
locations. Because participants were nonactive and nonathletes, they may have reacted
differently to exercise or to the treatment than an athlete and the data can therefore only be
applied to a general population. Further research would need to be performed on athletes to
understand how PBMT treatments may affect their sport. We also did not have a true control
group of participants who received no treatment. Therefore, we do not fully understand the
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extent to which the placebo effect may have contributed to having no significance in reducing
markers of muscle damage in the pulsed treatment group. However, studies similar to ours have
seen significant differences between treatment and placebo groups without true control
groups.11,12
CONCLUSION
We found participants in the continuous PBMT group had increased pain and decreased
function as a result of muscle-damaging exercise. Those treated with continuous PBMT also had
decreased isometric contraction strength when compared to other groups. Participants irradiated
with pulsed PBMT had no significant difference in markers of muscle damage when compared to
the placebo treatment. It appears that pulsed PBMT has no effect on muscle damage after
exercise. Although continuous PBMT was detrimental for most markers of muscle damage, it
aided in recovery and decreased isokinetic force loss. This study increases our knowledge of
proper parameters when using red/blue light PBMT. However, further research should explore
the effects of a single treatment of red/blue PBMT to determine whether they are similar to
previous studies performing a single treatment with red/infrared PBMT.
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Figure 1. PBMT electrode patch placement
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Figure 2. Modified VAS form participants used to present their level of soreness
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Figure 3. Isokinetic Average of Peak Torque. Data are means ± SE and are normalized to the
participants’ baseline value. * indicates significant difference between average isokinetic values
(P<0.05).
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Figure 4. Isokinetic peak torque (A), average peak torque (B), and average power (C). Data are
means ± SE and are normalized to the participants’ baseline value.
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Figure 5. Isometric Peak Torque. Data are means ± SE and are normalized to the participants’
baseline value. * indicates significant difference between average isometric values (P<0.05).
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Figure 6. Isometric peak torque (A), average peak torque (B). Data are means ± SE and are
normalized to the participants’ baseline value.
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A.

B.

Figure 7. VAS scores (A), LEFS scores (B). Data are means ± SE and are normalized to the
participants’ baseline value. * indicates significant difference between average muscle soreness
values (P<0.05).
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Figure 8. VAS score (A), LEFS score (B). Data are means ± SE and are normalized to the
participants’ baseline value.
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Figure 9. Means and standard deviations for Log of Creatine Kinase levels after exercise.
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